Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest

This article was originally published in RPM Report

Executive Summary

The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.

Advertisement

Related Content

Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Repatha and Praluent Launches Earn Praise From Express Scripts; Will Investors Applaud As Well?
Fixing Drug Pricing? Congress Enacts Generic Inflation Rebate And Turns Up Heat On FDA
A Safe Start To Bipartisan Pricing Action

Topics

Advertisement
UsernamePublicRestriction

Register